Bayer lymphoma treatment speeds to FDA approval
September 18, 2017Sales and Marketing Aliqopa, Bayer, biotech, drugs, pharma, pharmaceutical
The FDA gave Bayer priority review for its treatment Aliqopa (copanlisib) in May of this year, and it quickly came …
Santhera ‘surprised’ by European rejection of DMD drug
September 18, 2017Sales and Marketing Duchenne Muscular Dystrophy, biotech, drugs, pharma, pharmaceutical, santhera
Santhera Pharmaceutical has announced the EMA’s CHMP rejected its treatment for Duchenne muscular dystrophy (DMD) but revealed that it planned …
Top Ten most popular articles on Pharmafile.com this week
September 15, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cosentyx, Eli Lilly, Martin Skreli, Teva, pharma, top ten
This week has been a particularly eventful one for the industry: among our top stories, Martin Shkreli finally heads to …
Pfizer receives prostate cancer drug boost with trial results
September 15, 2017Medical Communications, Research and Development Astellas, Pfizer, Xtandi, biotech, drugs, pharma, pharmaceutical
Pfizer, and its partner Astellas Pharma, received a major boost to its plans for prostate cancer treatment, Xtandi, by announcing …
FDA approves first-ever biosimilar for cancer treatment
September 15, 2017Medical Communications, Sales and Marketing Amgen, Cancer, FDA, Mvasi, avastin, biosimilar
The FDA has announced the news that it has awarded approval to the first-ever biosimilar for the treatment of cancer …
GSK receives positive opinion for triple-therapy inhaler
September 15, 2017Medical Communications, Sales and Marketing GSK, biotech, drugs, pharma, pharmaceutical
GSK, alongside its partner Innoviva, has announced that it has received a positive opinion from the EMA’s CHMP for its …
Sandoz psoriasis biosimilar tops reference product Humira in latest Phase 3 data
September 15, 2017Medical Communications, Research and Development AbbVie, Humira, Novartis, Sandoz, adalimumab, biosimilar, biosimilars, pharma, pharmaceutical
Sandoz, the biologics and generics division of Novartis, has unveiled new Phase 3 data confirming the efficacy and safety profile …
Recipharm and Kancera collaborate to manufacture clinical trial supply
September 14, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Recipharm
Recipharm, a leading contract development and manufacturing organisation (CDMO) and Kancera, a development company focused on cancer therapy, have signed …
AstraZeneca’s Forxiga displays potential in type 1 diabetes
September 14, 2017Research and Development AstraZeneca, Forxiga, biotech, drugs, farxiga, pharma, pharmaceutical
Forxiga is AstraZeneca’s treatment for those living with type 2 diabetes but the results from a new trial have found …
GDPR and Human Data Samples: Being ‘somewhat prepared’ is not enough
September 14, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GDPR, biotech, data, drugs, pharma, pharmaceutical
Thomas Hirse, Partner, and Paetrick Sakowski, Associate, CMS, discuss what pharmaceutical companies need to be aware of ahead of the …
FDA panel gives GSK’s Shingrix unanimous approval
September 14, 2017Sales and Marketing GSK, Shingrix, biotech, drugs, pharma, pharmaceutical, shingles
The FDA’s advisory panel has given a strong signal that GSK’s Shingrix should not have too much difficulty getting full …
Novo’s Xultophy beats basal insulin in cutting cardiovascular risk
September 14, 2017Research and Development Novo Nordisk, Xultophy, diabetes, pharma, pharmaceutical, type 2 diabetes
Novo Nordisk has unveiled new data on its diabetes treatment Xultophy (insulin degludec/liraglutide) which supports its efficacy in reducing risk …
‘Pharma bro’ Shkreli heads to jail
September 14, 2017Medical Communications Martin Shkreli, Shkreli, biotech, drugs, pharma, pharmaceutical
Martin Shkreli’s habit of being unable to stay out of the headlines continues, although this time with the repercussion that …
Amicus pulls plug on rare skin disease drug after Phase 3 failure
September 14, 2017Research and Development Amicus, epidermolysis bullosa, pharma, pharmaceutical, trial failure
New Jersey-based biotech firm Amicus Therapeutics has been forced to terminate its development of its candidate for treating rare skin …
UK collaboration presents promising data in the fight against antibiotic resistance
September 13, 2017Research and Development Auspherix, antibiotic resistance, domainex, pharma
The collaborative efforts of Domainex and Auspherix have made new progress in the development of a solution to the growing …
Sanofi/Regeneron new asthma data bolstered by potential indications
September 13, 2017Research and Development Dupixent, Regeneron, Sanofi, biotech, drugs, pharma, pharmaceutical
Sanofi and Regeneron’s Dupixent is predicted to grow to be one of the largest selling drugs in the industry but …
Novartis’ Cosentyx proves long-term efficacy in psoriasis skin clearance
September 13, 2017Research and Development Cosentyx, Novartis, pharma, pharmaceutical, psoriasis
At the European Academy of Dermatology and Venereology Congress in Geneva, Switzerland, Novartis unveiled new Phase 3 data for Cosentyx …
23andMe raises $250m in financing, research points towards its future
September 13, 2017Research and Development, Sales and Marketing 23andME, biotech, drugs, pharma, pharmaceutical
23andMe made two announcements on the same day that point towards the future of its business: it revealed it had …
Recipharm and CTC launch integrated first in human service
September 13, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Recipharm, biotech, drugs, pharma, pharmaceutical
Contract development and manufacturing organisation (CDMO) Recipharm and contract research organisation (CRO) Clinical Trial Consultants (CTC) have partnered to launch …
Newly adopted flu vaccine could save 1,700 lives
September 12, 2017Research and Development, Sales and Marketing biotech, drugs, flu, fluad, pharma, pharmaceutical, seqirus
The Fluad flu vaccine, produced by Seqirus, was approved by the MHRA for use beginning in 2018 and further data …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
